Toggle Main Menu Toggle Search

Open Access padlockePrints

Molecular basis for treatment of mitochondrial myopathies

Lookup NU author(s): Professor Robert Taylor, Dr Theresa Wardell, Professor Robert Lightowlers, Emeritus Professor Doug Turnbull


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Mitochondrial DNA (mtDNA) is the only autonomously replicating source of DNA outside the nucleus. The mitochondrial genome encodes thirteen essential polypeptides of the mitochondrial respiratory chain. Defects of the mitochondrial genome can cause severe neurological and multi-systemic disorders. In many patients there is a mixture of mutated and wild-type mtDNA in the same cell (a situation termed heteroplasmy). In these patients the ratio of mutated to wild-type mtDNA is crucial and a biochemical defect only occurs with relatively high levels of mutated mtDNA within an individual cell. This threshold also seems to be critical in the development of mtDNA disease. Since the genetic defect causes a dysfunction in the terminal stage of oxidative metabolism, there is little potential for pharmacological intervention. Molecular techniques must be developed to reverse the ratio of mutated and wild-type mtDNA. In this paper we summarise our approach using both antigenomic peptide nucleic acids and cell necrosis. © Springer-Verlag 2000.

Publication metadata

Author(s): Wardell TM; Lightowlers RN; Taylor RW; Turnbull DM

Publication type: Article

Publication status: Published

Journal: Neurological Sciences

Year: 2000

Volume: 21

Issue: 9

Pages: S909-S912

Print publication date: 01/01/2000

ISSN (print): 1590-1874

ISSN (electronic): 1590-3478

Publisher: Springer Italia Srl


DOI: 10.1007/s100720070002

PubMed id: 11382188


Altmetrics provided by Altmetric